Company news
ANI Pharmaceuticals, Inc. news in 2022
ANI Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
December 18, 2022
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
November 27, 2022
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
November 15, 2022
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
November 8, 2022
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8: 00 a.m. ET
October 23, 2022
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
September 11, 2022
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
August 28, 2022
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
August 15, 2022
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
August 7, 2022
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
August 2, 2022
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
July 27, 2022
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8: 00 a.m. ET
July 24, 2022
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
July 17, 2022
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
June 21, 2022
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
June 20, 2022
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
June 1, 2022
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
May 31, 2022
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
May 19, 2022
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
May 9, 2022
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
April 18, 2022
ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
April 10, 2022
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
March 21, 2022
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
March 14, 2022
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
March 6, 2022
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
February 23, 2022
Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Exclusivity
February 13, 2022
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
January 23, 2022
ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 2, 2022
Calls in 2022
- ANI Pharmaceuticals (NASDAQ:ANIP) Q3 2022 Earnings Call
Nov 9, 2022
Transcript - ANI Pharmaceuticals (NASDAQ:ANIP) Q2 2022 Earnings Call
Aug 8, 2022
Transcript - ANI Pharmaceuticals (NASDAQ:ANIP) Q1 2022 Earnings Call
May 10, 2022
Transcript - ANI Pharmaceuticals (NASDAQ:ANIP) Q4 2021 Earnings Call
Mar 15, 2022
Transcript
Decks in 2022
- H.C. Wainwright Annual Global Investment Conference 2022
Conference · 15 slides · September 2022